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Abstract
Background:  Electroacupuncture (EA) has been reported to produce anti-edema and anti-
hyperalgesia effects on inflammatory disease. However, the mechanisms are not clear. The present
study investigated the biochemical mechanisms of EA anti-inflammation in a rat model.
Methods: Three experiments were conducted on male Sprague-Dawley rats (n = 7–8/per group).
Inflammation was induced by injecting complete Freund's adjuvant (CFA) subcutaneously into the
plantar surface of one hind paw. Experiment 1 measured plasma corticosterone (CORT) levels to
see if EA regulates CORT secretion. Experiment 2 studied the effects of the adrenal gland on the
therapeutic actions of EA using adrenalectomy (ADX) rats. Experiment 3 determined whether a
prototypical glucocorticoid receptor antagonist, RU486, affects EA anti-edema. EA treatment, 10
Hz at 3 mA and 0.1 ms pulse width, was given twice, for 20 min each, once immediately after CFA
administration and again 2 h post-CFA. Plasma CORT levels, paw thickness, indicative of the
intensity of inflammation, and paw withdrawal latency (PWL) were measured 2 h and 5 h after the
CFA injection.
Results: EA significantly increased plasma corticosterone levels 2 h (5 folds) and 5 h (10 folds) after
CFA administration compared to sham EA control, but EA alone in naive rats and CFA alone did
not induce significant increases in corticosterone. Adrenalectomy blocked EA-produced anti-
edema, but not EA anti-hyperalgesia. RU486 (15 μl, 15 μg/μl), a prototypical glucocorticoid
receptor antagonist, also prevented EA anti-edema.
Conclusion:  The data demonstrate that EA activates the adrenals to increase plasma
corticosterone levels and suppress edema and suggest that EA effects differ in healthy subjects and
in those with pathologies.
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1. Background
Non-steroidal anti-inflammatory drugs (NSAIDs) and
recently developed cyclooxygenase-2 (Cox-2) inhibitors
are commonly used for treating inflammatory diseases
such as arthritis. They are, however, associated with
adverse effects such as gastrointestinal disturbances and
cardiovascular risks [1-4]. Acupuncture, a therapeutic
modality with few or no adverse effects, has been used in
China and other Asian countries for thousands of years to
treat a variety of conditions, including inflammatory dis-
ease [5,6]. Clinical trials show that electroacupuncture
(EA) has beneficial effects in patients with various inflam-
matory diseases [7]. A recent clinical trial reported that EA
significantly alleviated the symptoms of patients with
knee osteoarthritis (OA) compared to sham acupuncture
control during a long follow-up period of 26 weeks [8].
We recently demonstrated that EA significantly inhibits
complete Freund's adjuvant (CFA)-induced hind paw
inflammation and hyperalgesia in a rat model [9,10].
Despite this evidence, the underlying mechanisms of acu-
puncture are still not understood.
Previous studies on uninjured animals reported that acu-
puncture increases adrenocorticotropic hormone (ACTH)
[11,12] and glucocorticoid [13-15]. Since adrenal glands
secrete glucocorticoids such as cortisol in humans [13]and
horses [14] and corticosterone (CORT) in rabbits [15],
these studies suggest that EA may activate the adrenals to
increase glucocorticoid secretion, leading to suppression
of inflammatory responses.
However, uninjured models do not mimic the chronic
pathological conditions seen clinically. For example,
chronic stress sensitize hypothalamic-pituitary-adrenal
axis (HPA) response to acute stress [16,17]. Interleukin-1
administration enhances HPA responses to foot shock in
rats [18]. Further, it has been demonstrated that EA may
produces differential effects under healthy and pathologi-
cal conditions [19]. Thus, we used a CFA-inflamed rat
model to test the hypothesis that EA increases glucocorti-




Male Sprague-Dawley rats weighing 280–350 g (Harlan,
Indianapolis, IN) were kept under controlled conditions
(22°C, relative humidity 40%–60%, 12-hour alternate
light-dark cycles, food and water ad libitum). The animal
protocols were approved by the Institutional Animal Care
and Use Committee (IACUC) at the University of Mary-
land School of Medicine.
2.2 Experimental design
Three experiments were conducted. In Experiment 1 we
measured CORT plasma levels to see if EA regulates CORT
secretion. Rats were divided into four groups (n = 8 per
group): CFA (0.08 ml) + EA, CFA + sham EA, CFA only,
and EA only. EA was applied at 10 Hz, 3 mA, 0.1 ms pulse
width for two 20 min periods, once at the beginning and
once at the end of a 2 h period starting immediately after
CFA injection. Blood (0.5 ml) was taken from each rat at
baseline (before inflammation and/or EA) and 2 h and 5
h after inflammation. In Experiment 2 adrenalectomy
(ADX) rats were used to study the effects of the adrenal
gland on the therapeutic actions of EA. Rats were divided
into two groups (n = 7 per group): 1) ADX rats + CFA
(0.03 ml) + EA, 2) ADX rats + CFA + sham EA. The degree
of edema, indicative of the intensity of inflammation, was
quantified 2 h and 5 h after CFA injection into a hind paw
by measuring paw thickness with a Laser Sensor (AR200–
50, Acuity, Portland, OR). A paw withdrawal latency
(PWL) test was conducted at the same time points. The
investigator who conducted the measurement was
blinded to the treatment assignments. Experiment 3 was
to determine whether a prototypical glucocorticoid recep-
tor antagonist, RU486, affects EA anti-edema. CFA (0.08
ml)-inflamed rats were divided into four groups (n = 7 per
group): RU486 (Sigma) + sham EA, vehicle + sham EA,
RU486 + EA and vehicle + EA. Paw thickness was meas-
ured as above. A 15 μg/μl concentration of RU486 was
dissolved in Dimethyl Sulfoxide (DMSO), and 15 μl of
RU486 or vehicle was injected locally into one hind paw
15 min before CFA injection.
2.3 Intravenous cannulation and blood sample collection
For intravenous cannulation, animals were anesthetized
with sodium pentobarbital (50 mg/kg) intraperitoneally
(i.p.) and surgically implanted with a chronic indwelling
jugular catheter (Braintree Scientific, Inc). The catheter
was secured with Mersilene surgical mesh (General Medi-
cal, New Haven, CT) at the jugular vein. It ran subcutane-
ously and exited at the animal's back through a 22-gauge
tubing secured with mesh. Antibiotic ointment was
applied to the wound. To prevent clogging, catheters were
flushed every third day with 0.15 ml of gentamicin (120
μg/ml). At baseline and 2 h and 5 h post-CFA 0.5 ml of
blood was withdrawn, and the lost volume was replaced
with an equal volume of saline. Blood was centrifuged
(1310 g) for 15 min at 4°C. The plasma was collected and
stored at -80°C until assayed. CORT levels were measured
with a commercially available ELISA kit (Cayman Chemi-
cal, MI) using the procedure recommended by the manu-
facturer. The detection limit of the kit is 24 ng/ml. The
antibody in the kit specifically reacts with CORT and has
less than 1% cross-reactivity with other adrenal hormones
(e.g. aldosterone and cortisone). CORT concentrationsBMC Complementary and Alternative Medicine 2007, 7:27 http://www.biomedcentral.com/1472-6882/7/27
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(ng/ml) were determined by comparing samples to the
standard curve generated with the kit.
2.4 ADX Surgery
Bilateral ADX surgery was performed via the dorsal
approach under anesthesia with sodium pentobarbital
(50 mg/kg, i.p.). The extracted tissue was dissected to con-
firm that both the adrenal cortex and adrenal medulla
were removed completely. The rats were given 0.9% saline
ad libitum to compensate for sodium loss after the opera-
tion and allowed to recover for five days before experi-
mentation. Blood was withdrawn and CORT was
measured as above on day 7 post-ADX.
2.5 Inflammation and hyperalgesia testing
Inflammation was induced by injecting CFA (0.5 mg/ml
heat-killed Mycobacterium tuberculosis suspended in an 1:1
oil/saline emulsion; Sigma, St. Louis, MO) subcutane-
ously into the plantar surface of one hind paw of each rat
using a 25-gauge hypodermal needle [20]. Inflammation
appeared within 2 h of the injection and peaked between
6–24 h. PWL was tested with a previously described
method [20,21]. Each rat was placed under an inverted
clear plastic chamber on the glass surface of the Paw Ther-
mal Stimulator System (UCSD, San Diego) and allowed
to acclimatize for 30 min before the test. A radiant heat
stimulus was applied to the plantar surface of each hind
paw from underneath the glass floor with a projector
lamp bulb (CXL/CXR, 8 V, 50 W). PWL to the nearest 0.1
sec was automatically recorded when the rat withdrew its
paw from the stimulus. Stimulus intensity was adjusted to
derive an average baseline PWL of approximately 10.0 s in
naive animals. Paws were alternated randomly to preclude
"order" effects. A 20-sec cut-off was used to prevent tissue
damage. Mean PWL was established by averaging the
latency of four tests with a 5-min interval between each
test.
2.6 Acupuncture Treatment Procedures
To maximize the anti-inflammatory effect and to treat ani-
mals prophylactically, the EA treatment was given twice,
for 20 min each, once immediately after the administra-
tion of CFA and again 2 h post-CFA [10]. EA parameters
of 10 Hz, 3 mA, 0.1 ms pulse width, which showed signif-
icant anti-inflammatory and anti-hyperalgesic effects on
the rat inflammation model in our previous studies
[9,10], were used in the present study.
The equivalent of the human acupoint Huantiao (GB30)
was chosen for bilateral needling based on traditional
Chinese medicine (TCM) meridian theory [6], on its suc-
cessful use in our previous studies, and on studies by oth-
ers [10,22,23]. Based on our previous point-specificity
study, EA produced better anti-hyperalgesia at GB30 than
at acupoint Waiguan (the fifth acupoint on the Triple
Energizer Meridian, TE 5) on the forepaw or at two non-
specific points, an abdominal point and a point on the
quadriceps opposite to GB30 [10]. Waiguan is located
dorsally between the radius and ulna, 2 units (based on
the standard acupuncture measurement of 12 units
between the transverse cubital crease and the transverse
wrist crease) above the transverse crease of the wrist.
Underneath are the posterior interosseous nerve and the
anterior interosseous nerve. In humans, GB30 is located at
the junction of the lateral 1/3 and medial 2/3 of the dis-
tance between the greater trochanter and the hiatus of the
sacrum; underneath are the sciatic nerve, inferior gluteal
nerve and gluteal muscles [5]. GB30 was located on the
rat's hind limbs using the comparable anatomical land-
marks. After cleaning the skin with alcohol swabs, a dis-
posable acupuncture needle (gauge # 32, 0.5 in long) was
inserted obliquely approximately one half inch deep into
GB30 on each of the animal's hind limbs, and a pair of
electrodes was attached to the ends of the needles. The
needles and the electrodes were stabilized with adhesive
tape.
EA stimulation was delivered by an electrical stimulator
(A300 Pulsemaster, World Precision Instruments) via an
isolator (A360D Stimulus Isolator, World Precision
Instruments) which converts electrical voltage into electri-
cal current. This bilateral, cross-limb connection has been
used previously by our team and others with no adverse
effects [10,24], and although similar connections are fre-
quently used in clinic, no adverse effects have ever been
reported [25,26]. While EA frequency was held constant,
intensity was adjusted slowly (over the period of approxi-
mately 2 min) to the designated level of 3 mA, which is
the maximum EA current intensity that a conscious ani-
mal can tolerate [10]. Mild muscle twitching was
observed. During EA treatment, each rat was placed under
an inverted clear plastic chamber (approximately 5" × 8"
× 11") but was neither restrained nor given anesthetic. The
animals remained awake and still during treatment and
showed no observable signs of distress. For the sham treat-
ment control, acupuncture needles were inserted bilater-
ally into GB30 without electrical stimulation or manual
needle manipulation. This sham procedure produced no
anti-hyperalgesic effect on this animal model in our previ-
ous study [10]. Because it is most comparable to the treat-
ment procedure but produces little therapeutic effect, we
used it as sham control in this study.
2.7 Data Analysis
For clarity, plasma CORT level data were presented as
changes in percentage: [(level 2–5h -levelbaseline)/levelbase-
line] × 100%. Paw thickness data were presented as mean ±
SE. PWL data were presented as (PWL 2–5h – PWL baseline)/
PWLbaseline *100%. Data were analyzed using analysis of
variance (ANOVA) with repeated measures followed byBMC Complementary and Alternative Medicine 2007, 7:27 http://www.biomedcentral.com/1472-6882/7/27
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post-hoc Tukey's multiple comparisons (GraphPad InStat).
P < 0.05 was set as the level of statistical significance.
3. Results
3.1 EA increased plasma levels of CORT
As shown in Fig. 1, plasma CORT levels in EA-treated
inflamed rats were significantly higher at 2 and 5 h post-
CFA injection than those in sham-treated inflamed rats,
the plasma CORT levels of which did not significantly
change compared to base levels during the same period.
The data indicate that EA effects on CORT may last at least
3 h. In contrast to CFA-inflamed rats, EA treatment of
non-inflamed rats produced no significant changes in
plasma CORT level. CFA-induced inflammation alone did
not caused significant plasma CORT changes.
3.2 ADX and RU486 blocked EA anti-edema
We previously reported that EA significantly inhibits
edema compared to sham EA control in CFA-injected rats
[9]. Fig. 2 shows that hind paw thickness was the same in
EA-treated and sham EA-treated CFA-injected ADX rats.
That EA had no effect on edema in ADX rats indicates that
ADX abolished the anti-edema effect of EA. In ADX rats,
plasma CORT significantly (P < 0.05) decreased from
baseline 7 days post-ADX, from 5087.85 ± 1017.64 to
394.78 ± 103.14 ng/ml.
In the RU486 study (Fig. 3.), paw thickness in EA-treated
rats plus vehicle was significantly less than that in sham
EA-treated rats plus vehicle, suggesting that EA signifi-
cantly inhibited edema compared to sham control. How-
ever, paw thickness in EA-treated rats plus RU486 was no
different from that in sham EA rats plus RU486, indicating
that RU486 blocked EA anti-edema.
3.3 ADX did not abolish EA anti-hyperalgesia
Fig. 4 shows the effects of ADX on EA-produced anti-
hyperalgesia. Before the CFA, overall mean baseline PWL
to noxious heat stimuli was similar in all groups of rats,
and there was no significant PWL difference between left
and right hind paws. Following an injection of 0.03-ml
CFA, PWL of the injected paw was significantly less than
that of the contralateral hind paw, which was unchanged
from baseline. EA treatment significantly (P < 0.05) inhib-
ited hyperalgesia 2 h post-CFA compared to sham EA in
ADX rats.
4. Discussion
The main findings of the present study are that EA acti-
vates the adrenal glands and increases endogenous CORT
to suppress inflammation. We found that EA significantly
increased plasma CORT levels in CFA-inflamed rats com-
pared to sham EA. Because CORT is mainly secreted by the
adrenals and has potent anti-inflammatory effects, an
increase of plasma CORT after EA treatment suggests that
EA activates the adrenals to suppress CFA-induced edema.
This is further evidenced by our experiments with ADX
rats and the glucocorticoid receptor antagonist, RU486.
Bilateral ADX completely blocked any EA-produced anti-
EA effects on edema in ADX rats Figure 2
EA effects on edema in ADX rats. The data were presented 
as mean ± SEM. All rats (n = 7 per group) were CFA-
inflamed. Note that EA did not inhibit edema in ADX rats. 
Edema was determined by increased paw thickness (mm).
Effects of EA treatment on plasma levels of CORT Figure 1
Effects of EA treatment on plasma levels of CORT. The data 
were presented as % changes vs baseline (n = 8 per group, 
mean ± SEM). EA treatment in non-inflamed rats (diamond) 
induced no significant changes of plasma CORT. CFA-
induced inflammation alone (triangle) resulted in no signifi-
cant changes in plasma CORT levels. EA treatment in 
inflamed rats (circle) significantly increased CORT levels 
compared to sham EA (square). *P < 0.05 compared sham 
EA.BMC Complementary and Alternative Medicine 2007, 7:27 http://www.biomedcentral.com/1472-6882/7/27
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edema effect. Pretreatment with RU486 also prevented EA
anti-edema. Taken together, these results suggest that EA
activates the adrenals in pathological conditions to
increase glucocorticoid secretion and suppress inflamma-
tory responses.
We also found that EA increased plasma CORT levels in
inflamed rats but did not affect levels in naive rats. Hypo-
thetically, stress responses during EA treatment might be
stronger in inflamed animals than in naive animals. How-
ever, we exclude this possibility because, as we reported
previously [9], the same stimulation intensity at acupoint
GB30 as that used in this study did not change heart rate
or blood pressure, both of which are indicators of stress
response, in CFA-inflamed animals. This demonstrates
that EA procedures and acupuncture needle stimulation
do not induce significant stress responses. Further, the
sham EA induced no changes in the plasma CORT levels
of inflamed rats, indicating that the EA procedures used in
this study have no stress effects. Thus we believe that the
CORT level increase in EA-treated CFA rats is not a general
stress response. The discrepancy between inflamed and
naive rats in response to the same EA treatment suggests
that EA affects healthy and pathological conditions differ-
ently. This is supported by a previous study reporting that
naloxone completely blocked EA analgesia in healthy rats
but partly blocked EA anti-hyperalgesia in carrageenan-
induced inflammatory rats, and EA analgesia lasted longer
in inflamed rats than in healthy rats [19]. Clinically, acu-
puncture produces long-term (days) pain relief in patients
[27], while it produces short-term (minutes) analgesia
[28] in healthy humans. Moreover, acupuncture signifi-
cantly decreases the systolic pressure in patients with
hypertension, but it did not exert significant influence on
either systolic or diastolic pressure in patients with nor-
mal blood pressure [29]. Collectively, these studies cor-
roborate our finding that EA works differently in healthy
than in pathological conditions. Others have reported,
however, that acupuncture increased serum levels of corti-
sol in healthy humans and horses [13,14]. This discrep-
ancy may be due to differences in the subjects used in the
studies.
It should be noted that bilateral ADX did not block EA
anti-hyperalgesia, suggesting that endogenous CORT
plays little part in EA anti-hyperalgesia. Consistent with
this, a previous study reported that endogenous CORT
does not reduce nociception in formalin-induced pain
model [30]. This suggests that EA may produce anti-
hyperalgesia by affecting the nervous system. Our previ-
ous studies demonstrated that spinal mu and delta opioid
systems are involved in EA anti-hyperalgesia in the same
inflammatory pain rat model [20].
5. Conclusion
The present study demonstrates that EA significantly
increases plasma CORT levels and suppresses edema by
activating the adrenal glands. It also suggests that EA pro-
Effects of RU486 on EA anti-edema in CFA-inflamed rats Figure 3
Effects of RU486 on EA anti-edema in CFA-inflamed rats. 
The data were presented as mean ± SEM. The hind paw 
thickness is the average of values at 2 h and 5 h and was ana-
lyzed with two-way ANOVA (n = 7 per group). EA + vehicle 
(column 1) significantly alleviated edema compared to sham + 
vehicle control (column 2). After RU486 pretreatment (col-
umns 3 & 4), EA showed no anti-edema effects (column 3) 
compared to sham control (column 4). * p < 0.05 compared 
to sham EA.
EA effects on hyperalgesia in ADX rats Figure 4
EA effects on hyperalgesia in ADX rats. The data were pre-
sented as mean ± SEM. All rats (n = 7 per group) were 
inflamed with CFA. Note that EA significantly inhibited 
hyperalgesia at 2.5 h post-CFA in ADX rats. Hyperalgesia 
was defined as a decrease in PWL (sec). * p < 0.05 compared 
to sham EA.BMC Complementary and Alternative Medicine 2007, 7:27 http://www.biomedcentral.com/1472-6882/7/27
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duces different effects in healthy and in pathological con-
ditions.
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